Cargando…
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Anti-programmed death (PD)-1 and PD-ligand (L)-1 checkpoint inhibitors have revolutionized the therapy of several cancers. Immunotherapy of cancer can offer long-term durable benefit to patients, is active regardless of tumour histology, has a unique immune-related safety profile, and can be used in...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549368/ https://www.ncbi.nlm.nih.gov/pubmed/28789707 http://dx.doi.org/10.1186/s12967-017-1278-5 |